Forge Therapeutics

OverviewSuggest Edit

Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. Forge has developed a fundamentally new approach for the discovery of metalloprotein inhibitors by focusing first on the metal in the enzyme active site. Using bio-inorganic and medicinal chemistry principles, full-length inhibitors are developed using a novel fragment growth strategy incorporating computational and structural biology.

TypePrivate
Founded2015
HQSan Diego, CA, US
Websiteforgetherapeutics.com

Latest Updates

Employees (est.) (May 2017)14
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Forge Therapeutics

Brian Dorsey

Brian Dorsey

Director
Mario Polywka

Mario Polywka

Director
John Schmid

John Schmid

Director
Zachary Zimmerman

Zachary Zimmerman

Co-Founder & CEO
Steve Worland

Steve Worland

Director
Andrew Tomaras

Andrew Tomaras

Chief Scientific Officer
Show more

Forge Therapeutics Office Locations

Forge Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
10578 Science Center Dr #205
Show all (1)

Forge Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Forge Therapeutics total Funding

$15 m

Forge Therapeutics latest funding size

$15 m

Time since last funding

5 years ago

Forge Therapeutics investors

Forge Therapeutics's latest funding round in April 2017 was reported to be $15 m. In total, Forge Therapeutics has raised $15 m
Show all financial metrics

Forge Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Forge Therapeutics Online and Social Media Presence

Embed Graph

Forge Therapeutics News and Updates

Forge Therapeutics To Present At The 18th Annual Needham & Company Healthcare Conference

SAN DIEGO, March 12, 2019 /PRNewswire/ -- Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that it will present a company overview and participate in 1x1 meetings at the 18th Annual Needham Healthcare Conference ...

Forge Therapeutics Blogs

Forge Therapeutics achieves CARB-X milestone for FG-LpxC LUNG antibiotic program

San Diego, California, September 22, 2021 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel anti-infectives targeting bacterial and viral metalloenzymes, announced today that it has been awarded further support from CARB-X of an additional $1.36M in option funding to advan…

Opinion: Antibiotic-resistant superbugs are a ticking time bomb in global health care

The global health-care system faces a ticking time bomb. Deadly bacteria and fungi are evolving to resist all current antimicrobials. If that happens, everything from chemotherapy to routine surgeries will become extraordinarily risky, since patients’ weakened immune systems won’t be able to fight o…

Forge Therapeutics appoints Andrew Tomaras, Ph.D. as Chief Scientific Officer

San Diego, California, June 3, 2021 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel anti-infectives targeting bacterial and viral metalloenzymes, announced today that Andrew Tomaras, Ph.D. has been appointed as Chief Scientific Officer. Dr. Tomaras will be responsible fo…

Improving data sharing to increase the efficiency of antibiotic R&D

Greater investment is needed in antibiotic R&D, and more must be done to maximize the impact of such investments. More widespread data sharing, such as the recent joint data contribution from Merck and Kyorin to the Pew Charitable Trusts’ SPARK platform, has a key role. The post Improving data s…

Forge Enters Into Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections

Forge is eligible to receive $190.5M in total payments SAN DIEGO, California, March 25, 2020 – Forge Therapeutics, Inc. (Forge) announced today that they have entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. (Roche) to license FG-LpxC LUNG, a novel antibiotic fo…

Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections

-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform-San Diego, California, Aug 14, 2019 –Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that the United States Patent and Trademark Office (US…
Show more

Forge Therapeutics Frequently Asked Questions

  • When was Forge Therapeutics founded?

    Forge Therapeutics was founded in 2015.

  • Who are Forge Therapeutics key executives?

    Forge Therapeutics's key executives are Brian Dorsey, Mario Polywka and John Schmid.

  • How many employees does Forge Therapeutics have?

    Forge Therapeutics has 14 employees.

  • Who are Forge Therapeutics competitors?

    Competitors of Forge Therapeutics include Selleck Chemicals, Mcneil and The Searle Company.

  • Where is Forge Therapeutics headquarters?

    Forge Therapeutics headquarters is located at 10578 Science Center Dr #205, San Diego.

  • Where are Forge Therapeutics offices?

    Forge Therapeutics has an office in San Diego.

  • How many offices does Forge Therapeutics have?

    Forge Therapeutics has 1 office.